Connect Biopharma Holdings Limited (CNTB)
NASDAQ · Manufacturing · Pharmaceutical preparations
$1.08−$0.0200 (−1.82%) on the dayAs of the close; data may be delayed.
CNTB price, last 12 months
Key stats
- Previous close
- $1.10
- Open
- $1.09
- Day range
- $1.06 – $1.12
- 52-week range
- $1.06 – $3.82
- Volume
- 803.8K
- Avg volume (20 days)
- 2.1M
- Market cap
- $68.0M
Performance
1W−15.6%
1M−53.7%
3M−50.7%
6M−70.7%
YTD−61.7%
1Y−37.2%
vs S&P 500, 1Y−54.0 pts
Technicals and fundamentals
About Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage biopharmaceutical company dedicated to transforming care for asthma and chronic obstructive pulmonary disease (COPD). The company is advancing rademikibart, a next-generation antibody designed to target interleukin-4-receptor alpha. It is currently conducting clinical studies of rademikibart for the treatment of acute exacerbations of asthma and COPD. The company operates in one operating segment: treatment of respiratory diseases.
- Sector
- Manufacturing
- Industry
- Pharmaceutical preparations
- Listed on
- NASDAQ
- Market cap
- $68.0M